Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Elacestrant and Everolimus in ER+/HER2-, ESR1-Mutated Advanced Breast Cancer Post-Endocrine and CDK4/6 Inhibitors
- Trial ID
- 2024-512926-27-00
- Protocol
- MEDOPP545
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this study is to demonstrate that **elacestrant** plus everolimus is superior to elacestrant plus placebo in prolonging **progression-free survival (PFS)** based on a Blinded Imaging Review Committee (BIRC) in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer (ABC) who have previously received endocrine therapy in combination with a CDK4/6 inhibitor. This is clinically relevant as it aims to improve the management of advanced breast cancer by potentially offering a more effective treatment option that could delay disease progression.
Secondary objectives include:
- Comparing investigator-assessed PFS based on local assessment between treatment groups in all patients.
- Comparing overall survival (OS) between treatment groups in all patients.
- Comparing objective response rate (ORR), clinical benefit rate (CBR), time to response (TTR), duration of response (DoR), and best percentage of change in tumor burden based on a BIRC between treatment groups in all patients.
- Comparing ORR, CBR, TTR, DoR, and best percentage of change in tumor burden based on local investigator assessment between treatment groups in all patients.
- Comparing the safety profile and tolerability between treatment groups in all patients.
- Describing the changes in health-related quality-of-life (HRQoL) assessments from baseline using the EuroQoL 5 Dimension 5 Level (EQ5D-5L), the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and EORTC Breast Cancer–Specific Quality of Life Questionnaire (EORTC QLQ-BR42) between treatment groups in all patients.
Participants
The clinical trial involves a total of **26 participants** diagnosed with **estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer** that has progressed following endocrine therapy and CDK4/6 inhibitors. The study population includes both male and female subjects aged **18 years and older**. Participants were selected based on their diagnosis and progression of the disease, with specific inclusion criteria ensuring they have not received prior chemotherapy for advanced disease and have adequate bone marrow and organ function. Lifestyle considerations such as diet and physical activity are not specified, but participants must meet certain health criteria, including fasting serum cholesterol and triglyceride levels within defined limits. The trial does not include a vulnerable population, and participants must have a minimum life expectancy of 12 weeks at screening. The selection process ensures that participants have a documented **ER[+]** and **HER2[-]** status, confirmed in a metastatic setting, and have not previously been treated with elacestrant or other investigational SERDs, PROTAC, CERAN, or novel SERM, and/or PI3K/AKT/mTOR inhibitors, including everolimus, for advanced disease.
Plans and Procedures
The clinical trial is designed as a **randomized**, **double-blind**, **placebo-controlled** phase 3 study. The primary objective is to evaluate the efficacy of **elacestrant** plus **everolimus** compared to elacestrant plus placebo in prolonging progression-free survival (PFS) in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced breast cancer. The trial is expected to commence recruitment in November 2024 and conclude by December 2027, with an estimated duration of participant involvement of up to 10 months.
Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on criteria such as measurable disease, adequate organ function, and prior treatment history. Following randomization, participants will attend regular follow-up visits to monitor treatment response and safety, utilizing assessments such as the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The end-of-study visit will occur upon completion of the treatment period or earlier if disease progression or unacceptable toxicity is observed.
Participants are expected to remain in the study for the full duration unless specific conditions necessitate early termination. These conditions include significant adverse events, withdrawal of consent, or non-compliance with study procedures. The trial will adhere to rigorous ethical standards, ensuring that all participants provide informed consent and that their safety is continuously monitored throughout the study.
Treatment
The clinical trial involves the administration of several **experimental medications** and non-experimental treatments. The primary experimental medication is **Everolimus**, marketed as Everolimus-ratiopharm® 2.5 mg tablets. This medication is presented in tablet form and is administered orally. The maximum daily dose is 7.5 mg, with a total maximum dose of 2100 mg over a treatment period of up to 10 weeks. Everolimus is a chemical substance and is not formulated for pediatric use.
Another experimental medication used in the trial is **Elacestrant**, available as ORSERDU film-coated tablets in two dosages: 86 mg and 345 mg. Both forms are administered orally, with a maximum daily dose of 345 mg and a total maximum dose of 96600 mg over a 10-week period. Elacestrant is also a chemical substance and is not intended for pediatric patients.
The trial also includes the use of **Goserelin Acetate**, administered as a subcutaneous injection. The maximum daily and total dose is 3.6 mg, with a treatment period of up to 10 weeks. Goserelin Acetate is a protein-based substance and is used according to clinical practice, showing benefits in premenopausal/perimenopausal and male breast cancer patients.
**Leuprorelin Acetate** is another non-experimental treatment used in the study, administered via subcutaneous injection. The maximum daily and total dose is 3.75 mg, with a treatment period of up to 10 weeks. Similar to Goserelin Acetate, Leuprorelin Acetate is a protein-based substance and is used according to clinical practice.
**Triptorelin Acetate** is also included in the trial as a non-experimental treatment, administered through subcutaneous injection. The maximum daily and total dose is 3.75 mg, with a treatment period of up to 10 weeks. Triptorelin Acetate is a protein-based substance and is used according to clinical practice.
**Betamethasone Sodium Phosphate** is used in the trial for the treatment of stomatitis (mucositis) through buccal use. The maximum daily and total dose is 40 ml, with a treatment period of up to 16 weeks. This chemical substance is administered as part of routine clinical practice, as there is no authorized pharmaceutical specialty for this indication.
The trial also includes a **placebo** in the form of white tablets, elongated, flat, with rounded edges, approximately 10 mm long and 4 mm wide, embossed with "EV" on one side and "2.5" on the other. The placebo tablets contain excipients such as lactose monohydrate, polyplasdone, cellulose microcrystalline, magnesium stearate, and hypromellose.
Efficacy
The efficacy of the clinical trial will be assessed primarily through **Progression-Free Survival (PFS)**, defined as the period from randomization to the first occurrence of disease progression or death from any cause, whichever occurs first. This will be evaluated by a Blinded Imaging Review Committee (BIRC) using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1). Secondary efficacy endpoints include investigator-assessed PFS, Overall Survival (OS), Objective Response Rate (ORR), Clinical Benefit Rate (CBR), Time to Response (TTR), Duration of Response (DoR), and the best percentage of change from baseline in the size of target tumor lesions. These will also be assessed using RECIST v.1.1 by both BIRC and local investigators.
Safety and tolerability will be evaluated through adverse events (AEs), treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), dose modifications, clinical laboratory parameters, electrocardiograms (ECGs), performance status, and vital signs. Patient-reported outcomes will be measured using changes from baseline in the EuroQoL 5 Dimension 5 Level (EQ-5D-5L), the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and the EORTC Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42) scales and symptom scores.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Patient or his/her legal representative must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures.
- Female or male patients ≥ 18 years of age at the time of signing ICF.
- Pre- or perimenopausal women, who do not meet the criteria for postmenopausal status (defined in continuation) and men must be concurrently receiving a LHRH analogue for at least 28 days (if shorter, post-menopausal levels of serum estradiol/follicle-stimulating hormone [FSH] must be confirmed analytically) prior to study randomization and are planning to continue LHRH agonist treatment during the study. Post-menopausal women as defined by any of the following criteria: o Age ≥ 60 years; o Age < 60 years and cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and serum estradiol and/or FSH levels within the laboratory’s reference range for post-menopausal females; o Documented bilateral surgical oophorectomy.
- Histologically- or cytologically proven diagnosis of adenocarcinoma of the breast with evidence of either unresectable locally recurrent or metastatic disease confirmed by computerized tomography (CT) scan or magnetic resonance imaging (MRI) that is not amenable to resection with curative intent.
- Documentation of ER[+] (≥10% positive stained cells) and HER2[-] (0–1+ by immunohistochemistry [IHC] or 2+ and negative by in situ hybridization [ISH] test) tumor according to the most recent American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines as per local assessment. ER[+]/HER2[-] status should be confirmed in metastatic setting, with exception of patients with bone and lung only disease.
- Patients with ESR1 mutation determined before randomization using Guardant360® CDx-CGP panel (Guardant Health) test. Note: Patients with previously determined ESR1 mutation using appropriately validated tests (such as Guardant360 CDx [Guardant Health], FoundationOne CDx, FoundationOne Liquid [Foundation Medicine Inc]) will be eligible for inclusion. This local determination can be performed either in blood or tumor samples.
- Radiological or objective evidence of disease progression on prior treatment with a CDK4/6 inhibitor in combination with endocrine therapy for advanced disease after at least 6 months of treatment. Patients receiving CDK4/6 inhibitor-based therapy in the adjuvant setting are also eligible provided that disease progression is confirmed after at least 12 months of treatment but no more than 12 months following CDK4/6 inhibitor treatment completion in this scenario.
- Patients must have previously received at least one and no more than two lines of endocrine therapy for ABC. Progression during or within 12 months of adjuvant endocrine therapy is considered as a line of endocrine therapy for advanced disease.
- No prior elacestrant or other investigational SERDs, PROTAC, CERAN, or novel SERM, and/or PI3K/AKT/mTOR inhibitors, including everolimus, for advanced disease are permitted. Note: Fulvestrant is permitted if treatment was administered at least 28 days before randomization.
- No prior chemotherapy for advanced disease is allowed.
- Evidence of measurable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v.1.1), or non-measurable, but evaluable, disease, including bone-only disease with at least one lytic or mixed lyticblastic bone lesion.
- Willingness and ability to provide the most recently available formalin-fixed paraffin-embedded (FFPE) tumor tissue or block. If a newly obtained baseline biopsy of an accessible tumor lesion is not possible to be obtained prior randomization, an archival tissue sample will be accepted.
- Fasting serum cholesterol ≤ 300 mg/dL or 7.75 mmol/L and fasting triglycerides ≤ 2.5 times the upper limit of normal (x ULN).
- Adequate bone marrow and organ function: o Hematological (without platelet, red blood cell transfusion, and/or granulocyte colony-stimulating factor support within seven days before randomization): absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelet count ≥ 100.0 x109/L; and hemoglobin ≥ 9.0 g/dL. o Hepatic: Serum albumin ≥ 2.5 g/dL; total serum bilirubin < 1.5 x ULN except for patients with Gilbert’s syndrome who may be included if the total serum bilirubin is ≤ 3 x ULN or direct bilirubin ≤ 1.5 x ULN; alkaline phosphatase (ALP) ≤ 2.5 x ULN (≤ 3 x ULN in patients with liver and/or bone metastases); aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 1.5 x ULN (≤ 3 x ULN in patients with liver metastases). o Renal: Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 50 mL/min as calculated by Cockcroft- Gault equation. o Coagulation: International normalized ratio (INR) ≤ 1.5 x ULN, unless that the patient meets the exception described in the exclusion criteria 16.
- Resolution of all acute toxic effects of prior anti-cancer therapy to grade ≤ 1 as determined by the National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v.5.0 (except for toxicities not considered a safety risk for the patient at Investigator's discretion). Note: Patients with grade 2 alopecia are allowed.
- Women of childbearing potential who are sexually active with a non-sterilized male partner must have a negative serum pregnancy test within 7 days before randomization. In addition, they agree to use one highly effective method of birth control 28 days prior to start of treatment until 120 days after the last dose of study treatments. Female patients must refrain from egg cell donation/freezing and breastfeeding during this same time period.
- Male participants with a female partner of childbearing potential must be surgically sterile or using a highly effective method of contraception 28 days prior to treatment until 120 days after the last dose of study treatments to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and 120 days after the last dose of study treatments is an acceptable practice if this is the preferred usual lifestyle of the participant.
- ECOG performance status of 0-1.
- Minimum life expectancy of ≥ 12 weeks at screening.
Exclusion Criteria
- Inability to comply with study and follow-up procedures.
- Formal contraindication to endocrine therapy defined as visceral crisis and/or rapidly or symptomatic progressive visceral disease.
- Current participation in another therapeutic clinical trial.
- Treatment with approved or investigational cancer therapy within 14 days prior to randomization except for fulvestrant that must be administered at least 28 days before randomization.
- Known active uncontrolled or symptomatic central nervous system (CNS) metastases and/or leptomeningeal disease as indicated by clinical symptoms, cerebral edema, and/or progressive growth. Patients with a history of CNS metastases are eligible if they have been previously treated with local therapy, are clinically stable, and off anti-convulsants and steroids for at least 14 days before randomization.
- Intact uterus with a history of endometrial intraepithelial neoplasia (atypical endometrial hyperplasia or higher-grade lesion).
- Concurrent malignancy or malignancy within three years before randomization with the exception of carcinoma in situ of the cervix, nonmelanoma skin carcinoma, or stage I uterine cancer. For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required.
- Known allergy or hypersensitivity reaction to any investigational medicinal products (IMPs) or their incorporated substances.
- History of malabsorption syndrome or other condition that would interfere with enteral absorption (ongoing gastrointestinal obstruction/motility disorder, malabsorption syndrome, or prior gastric bypass) or results in the inability or unwillingness to swallow pills.
- Palliative radiotherapy with a limited field of radiation within two weeks or with wide field of radiation or to more than 30% of the bone marrow within four weeks prior to randomization.
- Major surgical procedure or significant traumatic injury within 14 days before randomization or anticipation of need for major surgery within the course of the study treatment.
- Clinically relevant cardiovascular/cerebrovascular disease and/or cardiac dysfunction or conduction abnormalities including, but not confined, to any of the following: o Symptomatic pericarditis, unstable angina pectoris, documented myocardial infarction, coronary/peripheral artery bypass graft, symptomatic cardiac heart failure (CHF) (New York Heart Association [NYHA] Class II-IV), or cerebrovascular accident including transient ischemic attack within six months before study randomization.
- Concurrent uncontrolled atrial fibrillation, other ongoing cardiac dysrhythmias grade ≥ 2 as determined by NCI-CTCAE v.5.0, or prolonged QTcF (> 480 msec).
- Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited, to any of the following: o Massive lung metastatic involvement (e.g., pleural effusion, lymphangitic carcinomatosis, etc.). o Any underlying pulmonary disorder (e.g., severe asthma, severe chronic obstructive pulmonary disease [COPD], restrictive lung disease, post COVID-19 pulmonary fibrosis, etc.). o Any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement (e.g., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.). o Prior pneumonectomy.
- History of non-infectious interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Coagulopathy or any history of coagulopathy within six months before study enrollment, including history of deep vein thrombosis or pulmonary embolism. However, patients with the following conditions will be allowed to participate: o Adequately treated catheter-related venous thrombosis occurring more than 28 days prior to randomization. o Treatment with an anticoagulant (e.g., warfarin or heparin) for a thrombotic event occurring more than six months before randomization, or for an otherwise stable and allowed medical condition (e.g., well controlled atrial fibrillation), provided dose and coagulation parameters (as defined by local standard of care) are stable for at least 28 days prior to randomization.
- Concomitant treatment with immunosuppressive agents or chronic corticosteroids use before randomization with the following exceptions: topical applications, inhaled sprays, eye drops, mouthwash, or local injections are allowed. Patients on stable low dose of corticosteroids (£ 10 mg/day of prednisone or equivalent) for at least two weeks before randomization are also permitted.
- Unable or unwilling to avoid over-the-counter medications, dietary/herbal supplements (e.g., St. John’s wort), and/or foods (e.g., grapefruit, pomelos, star fruit, Seville oranges and their juices) that are moderate/strong inhibitors or inducers of CYP3A4 activity. Participation will be allowed if the medication, supplements, and/or foods are discontinued for at least five halflives or 14 days (whichever is shorter) prior to randomization and for the duration of the study
- Pregnant or lactating women or patients not willing to apply highly effective contraception as defined in the protocol.
- Current known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA. Any other active uncontrolled infection at the time of screening is not allowed.
- Known substance abuse or any other concurrent severe and/or uncontrolled psychiatric or medical condition that would, in the Investigator’s judgment, contraindicate patient participation.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
 Austria | Not Yet Recruiting | 01 Nov 2024 | 5 |
 Czechia | Not Yet Recruiting | 01 Nov 2024 | 18 |
 France | Not Yet Recruiting | 01 Nov 2024 | 36 |
 Germany | Not Yet Recruiting | 01 Nov 2024 | 18 |
 Greece | Not Yet Recruiting | 01 Nov 2024 | 20 |
 Italy | Recruiting | 01 Nov 2024 | 38 |
 Spain | Recruiting | 01 Nov 2024 | 79 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Everolimus-ratiopharm® 2,5 mg Tabletten | Test | TABLETTEN | ORAL | 7.5 | 10 | PRD5566472 |
GOSERELIN | Other | PHF00104MIG | SUBCUTANEOUS INJECTION | 3.6 | 10 | SCP111850463 |
ORSERDU 86 mg film-coated tablets | Test | FILM-COATED TABLETS | ORAL | 345 | 10 | PRD10641183 |
ORSERDU 345 mg film-coated tablets | Test | FILM-COATED TABLETS | ORAL | 345 | 10 | PRD10641184 |
LEUPRORELIN | Other | PHF00231MIG | SUBCUTANEOUS INJECTION | 3.75 | 10 | SCP151923 |
DEXAMETHASONE | Other | PHF00169MIG | BUCCAL USE | 40 | 16 | SCP10332310 |
The investigational product is as follows: white tablets, elongated, flat, rounded edges, about 10 mm
long and 4 mm wide, with the embossing "EV" on one side and "2.5" on the other side.
The list of excipients of Placebo tablet is as follows: Lactose monohydrate, Polyplasdone, Cellulose
microcrystalline, Magnesium stearate, Hypromellose. | Placebo | N/A | — | — | — | N/A |
TRIPTORELIN | Other | PHF00231MIG | SUBCUTANEOUS INJECTION | 3.75 | 10 | SCP1035124 |